FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

Supplemental application for JANUMET (sitagliptin and metformin HCl) submitted by Merck to FDA for a label-related or indication-related change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Janumet (sitagliptin/metformin)

Snippet

SUPPL AP for JANUMET (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)